Federal Data Hub › HRSA 340B · JSON
Hampton Site · 340B ID STD63139
Not participatingSTD
The CentralWest Immunologic Research Foundation is a STD enrolled in the federal 340B Drug Pricing Program in St. Louis, MO. The program lets qualifying providers buy outpatient drugs at deep federal discounts. This entity reports 20 contract-pharmacy arrangement(s) (0 currently active) — the third-party pharmacies that dispense its 340B-discounted drugs.
| Pharmacy | Location | Begin | Terminated | Pharmacy ID |
|---|---|---|---|---|
| SCHNUCK MARKETS INC | SAINT LOUIS, MO | 2020-01-01 | 2020-09-02 | 61443 |
| SCHNUCK MARKETS, INC. | SAINT LOUIS, MO | 2020-01-01 | 2020-09-02 | 61676 |
| SCHNUCK MARKETS, INC. | SAINT LOUIS, MO | 2020-01-01 | 2020-09-02 | 89568 |
| SCHNUCKS PHARMACY #301 | SAINT LOUIS, MO | 2020-01-01 | 2020-09-02 | 61418 |
| WALGREEN CO | SAINT LOUIS, MO | 2020-01-01 | 2021-07-01 | 61434 |
| WALGREEN CO. | BRENTWOOD, MO | 2021-01-01 | 2021-07-01 | 61675 |
| WALGREEN CO. | CLAYTON, MO | 2021-01-01 | 2021-07-01 | 61501 |
| WALGREEN CO. | CREVE COEUR, MO | 2020-04-27 | 2021-07-01 | 110297 |
| WALGREEN CO. | SAINT LOUIS, MO | 2020-01-01 | 2021-07-01 | 61445 |
| WALGREEN CO. | SAINT LOUIS, MO | 2020-04-27 | 2021-07-01 | 61427 |
| WALGREEN CO. | SAINT LOUIS, MO | 2021-01-01 | 2021-07-01 | 61667 |
| WALGREEN CO. | SAINT LOUIS, MO | 2020-04-27 | 2021-07-01 | 61496 |
| WALGREEN CO. | SAINT LOUIS, MO | 2020-04-27 | 2021-07-01 | 61633 |
| WALGREEN CO. | ST LOUIS, MO | 2020-01-01 | 2021-07-01 | 61635 |
| WALGREEN CO. | ST LOUIS, MO | 2020-04-27 | 2021-07-01 | 61468 |
| WALGREEN CO. | ST LOUIS, MO | 2021-01-01 | 2021-07-01 | 61504 |
| WALGREEN CO. | ST LOUIS, MO | 2021-01-01 | 2021-07-01 | 61493 |
| WALGREEN CO. | ST LOUIS, MO | 2020-04-27 | 2021-07-01 | 61476 |
| WALGREEN CO. | ST LOUIS, MO | 2020-01-01 | 2021-07-01 | 61446 |
| WALGREEN CO. | ST LOUIS, MO | 2020-01-01 | 2021-07-01 | 61453 |
Click a Pharmacy ID to see every other 340B entity using that same pharmacy.
The 340B Drug Pricing Program (Public Health Service Act §340B) requires drug manufacturers to sell outpatient drugs to enrolled "covered entities" — disproportionate-share hospitals, federally qualified health centers, and specialized clinics — at significant discounts. Covered entities increasingly contract with third-party "contract pharmacies" to dispense these drugs, a practice that has grown explosively and drawn scrutiny over how the discounts are used. This page mirrors HRSA's Office of Pharmacy Affairs (OPAIS) public registry.
Source: HRSA OPAIS. License: CC0 1.0. Snapshot 2026-06-25.